DRI Ecstasy Plus Assay

FDA 510(k) K240670 · Microgenics Corporation

Substantially Equivalent

510(k) numberK240670

Submission

Device name
DRI Ecstasy Plus Assay
Applicant
Microgenics Corporation
Fremont, CA, US
Received
March 11, 2024
Decision date
October 30, 2024
Decision
Substantially Equivalent (SESE)
Type
Special 510(k)
Summary
510(k) summary available from FDA

Official FDA 510(k) record

Device classification

Product code
DKZ – Enzyme Immunoassay, Amphetamine
Device class
Class II (moderate risk)
Regulation
21 CFR 862.3100
Specialty
Clinical Toxicology

Other 510(k)s with product code DKZ

510(k)DeviceApplicantDecision
K233019AllTest Multi-Drug Rapid Test Cup; AllTest Multi-Drug Rapid Test Panel; AllTest…DKZ · Traditional Hangzhou AllTest Biotech Co., Ltd.12/13/2023SE
K231137Xenta Drug Screen Cup, Xenta Drug Screen DipcardDKZ · Traditional Xenta Biomedical Science Co., Ltd.05/19/2023SE
K200363Quidel Triage® TOX Drug Screen, 94600DKZ · Special Quidel Cardiovascular, Inc.03/11/2020SE
K191099Atlas Multi-Drugs Screening Test Cup, Atlas Multi-Drugs Screening Test PanelDKZ · Traditional Atlas Medical10/03/2019SE
K182719Quidel Triage TOX Drug Screen, 94600; Quidel Triage® MeterProDKZ · Traditional Quidel Cardiovascular, Inc.06/19/2019SE
K182738Single and Multi-Drug Rapid Test Panel With Adulteration (Urine), Single and Multi-Drug…DKZ · Traditional Hangzhou AllTest Biotech Co., Ltd.03/27/2019SE
K180879BIO-VENTURE Rapid Multi-Drug Test Easy Cup for OTC Use, BIO-VENTURE Rapid Multi-Drug…DKZ · Traditional Shanghai Venture Bio-Tech Co., Ltd.12/14/2018SE
K181945QuickScreen Pro Multi Drug Screening Test, Model 9395ZDKZ · Traditional Phamatech, Inc.10/18/2018SE
K173303INSTANT-VIEW plus Multi-Drug of Abuse Urine Test - Simple Cup (OTC Use), INSTANT-VIEW…DKZ · Traditional Alfa Scientific Designs, Inc.02/23/2018SE
K161251CLUNGENE Amphetamine Tests, CLUNGENE Cocaine Tests, CLUNGENE Oxazepam TestsDKZ · Traditional Hangzhou Clongene Biotech Co., Ltd.08/30/2016SE

More from Hangzhou Clongene Biotech Co., Ltd.

510(k)DeviceDecision
K243498Alinity c Benzodiazepines Reagent KitJXM · Special 12/11/2024SE
K231020Alinity c Tricyclic Antidepressants Reagent KitLFH · Traditional 11/17/2023SE
K231007CEDIA Heroin Metabolite (6-AM) AssayDJG · Traditional 09/27/2023SE
K213875DRI TM Tricyclics Serum Tox AssayLFH · Traditional 12/21/2022SE
K211973DRI Cocaine Metabolite AssayDIO · Traditional 09/24/2021SE
K192943CEDIA Heroin Metabolite (6-AM) assayDJG · Traditional 12/16/2019SE
K190968CEDIA Benzodiazepine AssayJXM · Traditional 12/09/2019SE
K181499DRI Cocaine Metabolite AssayDIO · Traditional 07/06/2018SE
K173963DRI Benzodiazepine AssayJXM · Traditional 02/21/2018SE
K173195DRI Hydrocodone AssayDJG · Traditional 02/13/2018SE

Questions and answers

When was DRI Ecstasy Plus Assay cleared by the FDA?

DRI Ecstasy Plus Assay (K240670) received a 510(k) decision of Substantially Equivalent on October 30, 2024, 233 days after the submission was received.

What is the product code of K240670?

The FDA product code is DKZ – Enzyme Immunoassay, Amphetamine, a Class II (moderate risk) device regulated under 21 CFR 862.3100.